Nov 26 (Reuters) - Acasti Pharma Inc ACST.V :
* ACASTI PHARMA REPORTS LAST PATIENT VISIT IN TRILOGY 1 PHASE 3 TRIAL OF CAPRE FOR THE TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA
* ACASTI PHARMA - EXPECTS LAST PATIENT TO COMPLETE FINAL VISIT IN TRILOGY 2 IN EARLY JAN 2020, WITH TOPLINE RESULTS EXPECTED TOWARDS END OF JAN 2020
* ACASTI PHARMA - IF TRILOGY 1, TRILOGY 2 RESULTS ARE POSITIVE, CO INTENDS TO FILE AN NDA BY MID-2020 TO OBTAIN REGULATORY APPROVAL FOR CAPRE IN U.S.
* ACASTI PHARMA INC - ON TRACK TO REPORT TOPLINE RESULTS FOR TRILOGY 1 IN DEC 2019 AND TRILOGY 2 IN JAN 2020